

CLEVELAND BIOLABS INC  
Form 8-K  
September 08, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of Earliest Event Reported): September 4, 2014**

**Cleveland BioLabs, Inc.**  
**(Exact Name of Issuer as Specified in Charter)**

**DELAWARE**  
**(State or Other Jurisdiction of**  
**Incorporation or Organization)**

**001-32954**  
**(Commission**  
**File Number)**  
**73 High Street**

**20-0077155**  
**(I.R.S. Employer**  
**Identification Number)**

Edgar Filing: CLEVELAND BIOLABS INC - Form 8-K

**Buffalo, NY 14203**

**(Address of Principal Executive Offices and zip code)**

**(716) 849-6810**

**(Registrant's Telephone Number, Including Area Code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 1.01 Entry into a Material Definitive Agreement.**

**Item 1.01(a): Settlement Agreement**

On September 4, 2014, Cleveland BioLabs, Inc. (the Company) entered into a settlement agreement (the Settlement Agreement) with Sabby Healthcare Volatility Master Fund, Ltd. (Sabby Healthcare) and Sabby Volatility Warrant Master Fund, Ltd. (Sabby Volatility, and collectively with Sabby Healthcare, Sabby) to resolve the pending claims against each other arising from the Company's sale of shares of its common stock, \$0.005 par value per share (the Common Stock), and warrants to purchase shares of its Common Stock (collectively, the Securities). The Securities were sold pursuant to a securities purchase agreement dated January 14, 2014.

Sabby has agreed to withdraw its claims without compensation from the Company, and the Company has agreed to waive any claims for legal fees and expenses from Sabby. The parties have exchanged mutual releases of liability.

On September 8, 2014, the Company issued a press release announcing the Settlement Agreement. A copy of the press release is attached as Exhibit 99.1.

**Item 1.01(b): Series A Warrant Amendments**

On September 4, 2014, the Company entered into an Amendment to Series A Common Stock Purchase Warrant with each of Sabby Healthcare and Sabby Volatility (collectively, the Series A Warrant Amendments) to amend certain terms of a warrant (collectively, the Series A Warrants), each dated January 16, 2014, by and between the Company and each of Sabby Healthcare and Sabby Volatility. The Series A Warrants entitle Sabby to purchase, in the aggregate, 2,049,180 shares of the Company's Common Stock. The Series A Warrant Amendments extend the expiration dates of the Series A Warrants from January 16, 2019 to January 16, 2021. Additionally, the Series A Warrant Amendments reduce the exercise price of the Series A Warrants from \$1.22 to \$1.02.

Each of the Series A Warrant Amendments are filed as exhibits to this Current Report on Form 8-K and are incorporated herein by reference. The foregoing is only a brief description of the material terms of the Series A Warrant Amendments and does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to the exhibits.

**Item 1.01(c) Series B Warrant Cancellation**

On September 4, 2014, the Company and Sabby entered into an agreement pursuant to which each of Sabby Healthcare and Sabby Volatility will return for cancellation a warrant, each dated January 16, 2014, by and between the Company and each of Sabby Healthcare and Sabby Volatility (collectively, the Series B Warrants). The Series B Warrants entitle Sabby to purchase, in the aggregate, 2,049,180 shares of the Company's Common Stock.

**Item 1.01(d): Securities Purchase Agreement Amendment**

On September 4, 2014 the Company entered into an Amendment No. 1 to Securities Purchase Agreement (the Purchase Agreement Amendment ) with each of Sabby Healthcare and Sabby Volatility to amend certain terms of that certain Securities Purchase Agreement, dated as of January 14, 2014, by and among the Company and certain institutional investors named on the signature pages attached thereto (the Purchase Agreement ). The Purchase Agreement Amendment removes from the Purchase Agreement restrictions on the Company's ability to effect an issuance involving a variable rate transaction.

The Purchase Agreement Amendment is filed as an exhibit to this Current Report on Form 8-K and is incorporated herein by reference. The foregoing is only a brief description of the material terms of the Purchase Agreement Amendment and does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to the exhibits.

**Item 3.03(a) Material Modification to Rights of Security Holders**

The information set forth in Item 1.01(b) and 1.01(d) of this Current Report on Form 8-K is incorporated by reference into this Item 3.03.

**Item 9.01 Financial Statements and Exhibits.**

(d)

**Exhibit**

<b>No.</b>	<b>Description</b>
4.1	Sabby Healthcare Series A Warrant Amendment
4.2	Sabby Volatility Series A Warrant Amendment
10.1	Purchase Agreement Amendment
99.1	Press Release titled Cleveland BioLabs and Sabby Announce Resolution of Litigation, dated September 8, 2014.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 8, 2014

**Cleveland BioLabs, Inc.**

By: /s/ YAKOV KOGAN  
Name: Yakov Kogan  
Title: Chief Executive Officer